Canadian researchers found that patients who took a combination of metformin and GlaxoSmithKline's Avandia in a low dose were two-thirds less likely to develop Type 2 diabetes. The treatment appeared to prevent progression from prediabetes to full Type 2 diabetes without causing adverse effects such as heart failure or fluid retention, which are typically associated with the drugs.

Full Story:

Related Summaries